INO PE Ratio & Valuation,Is INO Overvalued

INO Relative Valuation

INO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INO is overvalued; if below, it's undervalued.

Historical Valuation

Inovio Pharmaceuticals Inc (INO) is now in the Fair zone, suggesting that its current forward PS ratio of 36.67 is considered Fairly compared with the five-year average of -2.95. The fair price of Inovio Pharmaceuticals Inc (INO) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：1.64

Fair

-1.33

0.00

EV/EBITDA

Inovio Pharmaceuticals Inc. (INO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.71. The thresholds are as follows: Strongly Undervalued below -7.48, Undervalued between -7.48 and -4.60, Fairly Valued between 1.17 and -4.60, Overvalued between 1.17 and 4.06, and Strongly Overvalued above 4.06. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.82

EV/EBIT

Inovio Pharmaceuticals Inc. (INO) has a current EV/EBIT of -0.82. The 5-year average EV/EBIT is -1.56. The thresholds are as follows: Strongly Undervalued below -6.06, Undervalued between -6.06 and -3.81, Fairly Valued between 0.69 and -3.81, Overvalued between 0.69 and 2.94, and Strongly Overvalued above 2.94. The current Forward EV/EBIT of -0.82 falls within the Historic Trend Line -Fairly Valued range.

36.67

Inovio Pharmaceuticals Inc. (INO) has a current PS of 36.67. The 5-year average PS is 400.76. The thresholds are as follows: Strongly Undervalued below -527.72, Undervalued between -527.72 and -63.48, Fairly Valued between 865.00 and -63.48, Overvalued between 865.00 and 1329.24, and Strongly Overvalued above 1329.24. The current Forward PS of 36.67 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Inovio Pharmaceuticals Inc. (INO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.35. The thresholds are as follows: Strongly Undervalued below -7.81, Undervalued between -7.81 and -5.08, Fairly Valued between 0.39 and -5.08, Overvalued between 0.39 and 3.12, and Strongly Overvalued above 3.12. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.41

P/FCF

Inovio Pharmaceuticals Inc. (INO) has a current P/FCF of -1.41. The 5-year average P/FCF is -2.16. The thresholds are as follows: Strongly Undervalued below -6.50, Undervalued between -6.50 and -4.33, Fairly Valued between 0.00 and -4.33, Overvalued between 0.00 and 2.17, and Strongly Overvalued above 2.17. The current Forward P/FCF of -1.41 falls within the Historic Trend Line -Fairly Valued range.

Inovio Pharmaceuticals Inc (INO) has a current Price-to-Book (P/B) ratio of -11.73. Compared to its 3-year average P/B ratio of -0.01 , the current P/B ratio is approximately 226370.81% higher. Relative to its 5-year average P/B ratio of 1.05, the current P/B ratio is about -1216.44% higher. Inovio Pharmaceuticals Inc (INO) has a Forward Free Cash Flow (FCF) yield of approximately -76.72%. Compared to its 3-year average FCF yield of -99.84%, the current FCF yield is approximately -23.15% lower. Relative to its 5-year average FCF yield of -70.35% , the current FCF yield is about 9.06% lower.

-11.73

P/B

Median3y

-0.01

Median5y

1.05

-76.72

FCF Yield

Median3y

-99.84

Median5y

-70.35

Competitors Valuation Multiple

The average P/S ratio for INO's competitors is 10.01, providing a benchmark for relative valuation. Inovio Pharmaceuticals Inc Corp (INO) exhibits a P/S ratio of 36.67, which is 266.31% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of INO decreased by 20.10% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 0.00 to 0.00.

The secondary factor is the Margin Expansion, contributed 55.68%to the performance.

Overall, the performance of INO in the past 1 year is driven by Revenue Growth. Which is more sustainable.

NaN%

0.00 → 0.00

Revenue Growth

55.68%

-87.21K → -135.76K

Margin Expansion

NaN%

NaN → -0.61

P/E Change

-20.10%

2.09 → 1.67

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Inovio Pharmaceuticals Inc (INO) currently overvalued or undervalued?

What is Inovio Pharmaceuticals Inc (INO) fair value?

INO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Inovio Pharmaceuticals Inc (INO) is between to according to relative valuation methord.

How does INO's valuation metrics compare to the industry average?

What is the current P/B ratio for Inovio Pharmaceuticals Inc (INO) as of Jan 08 2026?

As of Jan 08 2026, Inovio Pharmaceuticals Inc (INO) has a P/B ratio of -11.73. This indicates that the market values INO at -11.73 times its book value.

What is the current FCF Yield for Inovio Pharmaceuticals Inc (INO) as of Jan 08 2026?

As of Jan 08 2026, Inovio Pharmaceuticals Inc (INO) has a FCF Yield of -76.72%. This means that for every dollar of Inovio Pharmaceuticals Inc’s market capitalization, the company generates -76.72 cents in free cash flow.

What is the current Forward P/E ratio for Inovio Pharmaceuticals Inc (INO) as of Jan 08 2026?

As of Jan 08 2026, Inovio Pharmaceuticals Inc (INO) has a Forward P/E ratio of -1.33. This means the market is willing to pay $-1.33 for every dollar of Inovio Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Inovio Pharmaceuticals Inc (INO) as of Jan 08 2026?

As of Jan 08 2026, Inovio Pharmaceuticals Inc (INO) has a Forward P/S ratio of 36.67. This means the market is valuing INO at $36.67 for every dollar of expected revenue over the next 12 months.

INO Valuation